Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effects of combination treatment with theophylline sustained-release tablets and thymalfasin on pulmonary function, immunity, and inflammation in elderly patients with chronic obstructive pulmonary disease and respiratory failure

Yu Liu , Chunhui Zhang, Xiulan Chen

Department of Pulmonary and Critical Care Medicine, Fujian Geriatric Hospital, Fuzhou, Fujian Province 350000, China;

For correspondence:- Yu Liu Email: liu_yu_0913@163.com Tel:+8613609559019

Accepted: 28 December 2022 Published: 31 January 2023

Citation: Liu Y, Zhang C, Chen X. Effects of combination treatment with theophylline sustained-release tablets and thymalfasin on pulmonary function, immunity, and inflammation in elderly patients with chronic obstructive pulmonary disease and respiratory failure. Trop J Pharm Res 2023; 22(1):167-174 doi: 10.4314/tjpr.v22i1.23

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of combined administration of theophylline sustained-release tablets and thymalfasin on pulmonary function, immunity, and inflammation in elderly patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.

Methods: A total of 122 elderly patients in Fujian Geriatric Hospital, Fuzhou, China who suffered from acute attack of COPD with respiratory failure from January 2019 - January 2020 were selected for this study. The patients were divided randomly and evenly into study and control groups. Theophylline sustained-release tablets were administered to subjects in the control group, while theophylline sustained-release tablets and thymalfasin were administered to subjects in the study group. Pulmonary function indicators, viz, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC), blood gas indicators (PaCO2, PaO2, and SaO2), inflammatory factors (sICAM-1, PGE2, and hs-CRP), immune cells (Th17, Treg, and Th17/Treg), as well as exercise ability (the 6 min walking distance test) were evaluated for each group. Adverse reactions were also assessed.

Results: There were no significant differences in pulmonary function, blood gas, inflammation, immunity, and exercise ability between the two groups before treatment (p < 0.01). However, all parameters improved significantly for both groups after treatment, with better outcomes for all parameters in the study group. A proportion of (14.75 %) patients in the study group showed adverse events, while 13.11 % of the patients in the control group exhibited adverse effects, meaning that the study group had a slightly but not significantly higher rate of adverse events.

Conclusion: The combined administration of theophylline sustained-release tablets and thymalfasin reduces inflammation and improves physical immunity, leading to enhancement of blood gas and pulmonary function in elderly patients with COPD and respiratory failure. However, further clinical trials are required prior to application of this combination therapy in clinical practice.

Keywords: Theophylline sustained-release tablets, Thymalfasin, Chronic obstructive pulmonary disease, Respiratory failure, Pulmonary function, Immunity, Inflamm